Which has higher earnings & valuation, COAG or BCYC?

Hemab Therapeutics has higher earnings, but lower revenue than Bicycle Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A N/A N/A Bicycle Therapeutics $72.86M 3.88 -$218.96M -$3.15 N/A

Bicycle Therapeutics (BCYC) Competitors

$4.05 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$4.04 -0.01 (-0.22%)

As of 06/12/2026 07:55 PM Eastern

Compare

BCYC vs. COAG, WVE, MPLT, PAHC, and MRVI

Should you buy Bicycle Therapeutics stock or one of its competitors? MarketBeat compares Bicycle Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bicycle Therapeutics include Hemab Therapeutics (COAG), WAVE Life Sciences (WVE), Maplight Therapeutics (MPLT), Phibro Animal Health (PAHC), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry.

How does Bicycle Therapeutics compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

In the previous week, Hemab Therapeutics had 1 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 2 mentions for Hemab Therapeutics and 1 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 1.87 beat Hemab Therapeutics' score of 0.93 indicating that Bicycle Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Hemab Therapeutics	Positive
Bicycle Therapeutics	Very Positive

86.2% of Bicycle Therapeutics shares are held by institutional investors. 8.5% of Bicycle Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Hemab Therapeutics presently has a consensus target price of $41.75, suggesting a potential upside of 67.13%. Bicycle Therapeutics has a consensus target price of $14.00, suggesting a potential upside of 245.68%. Given Bicycle Therapeutics' higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

Hemab Therapeutics has higher earnings, but lower revenue than Bicycle Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
Bicycle Therapeutics	$72.86M	3.88	-$218.96M	-$3.15	N/A

Hemab Therapeutics has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -344.95%. Hemab Therapeutics' return on equity of 0.00% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%

Summary

Bicycle Therapeutics beats Hemab Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Bicycle Therapeutics compare to WAVE Life Sciences?

Bicycle Therapeutics (NASDAQ:BCYC) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

WAVE Life Sciences has a net margin of -255.70% compared to Bicycle Therapeutics' net margin of -344.95%. Bicycle Therapeutics' return on equity of -35.74% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

Bicycle Therapeutics presently has a consensus price target of $14.00, indicating a potential upside of 245.68%. WAVE Life Sciences has a consensus price target of $26.41, indicating a potential upside of 349.94%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than Bicycle Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 8.5% of Bicycle Therapeutics shares are owned by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

WAVE Life Sciences has lower revenue, but higher earnings than Bicycle Therapeutics. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	3.88	-$218.96M	-$3.15	N/A
WAVE Life Sciences	$42.73M	26.43	-$204.38M	-$1.06	N/A

In the previous week, WAVE Life Sciences had 6 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 7 mentions for WAVE Life Sciences and 1 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 1.87 beat WAVE Life Sciences' score of 0.88 indicating that Bicycle Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Bicycle Therapeutics	Very Positive
WAVE Life Sciences	Positive

Bicycle Therapeutics has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.33, suggesting that its share price is 233% less volatile than the broader market.

Summary

WAVE Life Sciences beats Bicycle Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Bicycle Therapeutics compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Maplight Therapeutics currently has a consensus target price of $37.78, suggesting a potential upside of 36.14%. Bicycle Therapeutics has a consensus target price of $14.00, suggesting a potential upside of 245.68%. Given Bicycle Therapeutics' higher probable upside, analysts plainly believe Bicycle Therapeutics is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.00
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

Maplight Therapeutics has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -344.95%. Maplight Therapeutics' return on equity of 0.00% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%

In the previous week, Maplight Therapeutics had 1 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 2 mentions for Maplight Therapeutics and 1 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 1.87 beat Maplight Therapeutics' score of 0.93 indicating that Bicycle Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Maplight Therapeutics	Positive
Bicycle Therapeutics	Very Positive

Maplight Therapeutics has higher earnings, but lower revenue than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
Bicycle Therapeutics	$72.86M	3.88	-$218.96M	-$3.15	N/A

86.2% of Bicycle Therapeutics shares are held by institutional investors. 3.8% of Maplight Therapeutics shares are held by insiders. Comparatively, 8.5% of Bicycle Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Maplight Therapeutics beats Bicycle Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Bicycle Therapeutics compare to Phibro Animal Health?

Bicycle Therapeutics (NASDAQ:BCYC) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Bicycle Therapeutics currently has a consensus target price of $14.00, suggesting a potential upside of 245.68%. Phibro Animal Health has a consensus target price of $38.80, suggesting a potential upside of 23.06%. Given Bicycle Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Bicycle Therapeutics is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Phibro Animal Health	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Bicycle Therapeutics has a beta of 1.54, meaning that its share price is 54% more volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market.

Phibro Animal Health has a net margin of 6.35% compared to Bicycle Therapeutics' net margin of -344.95%. Phibro Animal Health's return on equity of 37.14% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
Phibro Animal Health	6.35%	37.14%	8.57%

In the previous week, Phibro Animal Health had 15 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 16 mentions for Phibro Animal Health and 1 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 1.87 beat Phibro Animal Health's score of 0.77 indicating that Bicycle Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Bicycle Therapeutics	Very Positive
Phibro Animal Health	Positive

86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are owned by institutional investors. 8.5% of Bicycle Therapeutics shares are owned by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Phibro Animal Health has higher revenue and earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	3.88	-$218.96M	-$3.15	N/A
Phibro Animal Health	$1.30B	0.99	$48.26M	$2.33	13.53

Summary

Phibro Animal Health beats Bicycle Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Bicycle Therapeutics compare to Maravai LifeSciences?

Bicycle Therapeutics (NASDAQ:BCYC) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Maravai LifeSciences has a net margin of -51.07% compared to Bicycle Therapeutics' net margin of -344.95%. Maravai LifeSciences' return on equity of -17.87% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
Maravai LifeSciences	-51.07%	-17.87%	-9.08%

Bicycle Therapeutics currently has a consensus price target of $14.00, indicating a potential upside of 245.68%. Maravai LifeSciences has a consensus price target of $5.50, indicating a potential upside of 10.44%. Given Bicycle Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Bicycle Therapeutics is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Maravai LifeSciences had 2 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 3 mentions for Maravai LifeSciences and 1 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 1.87 beat Maravai LifeSciences' score of 0.64 indicating that Bicycle Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Bicycle Therapeutics	Very Positive
Maravai LifeSciences	Positive

Bicycle Therapeutics has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.71, indicating that its share price is 29% less volatile than the broader market.

86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 8.5% of Bicycle Therapeutics shares are owned by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Maravai LifeSciences has higher revenue and earnings than Bicycle Therapeutics. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	3.88	-$218.96M	-$3.15	N/A
Maravai LifeSciences	$185.74M	6.92	-$130.77M	-$0.71	N/A

Summary

Bicycle Therapeutics and Maravai LifeSciences tied by winning 8 of the 16 factors compared between the two stocks.

Get Bicycle Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCYC vs. The Competition

Export

Metric	Bicycle Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$282.73M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-1.29	20.00	24.00	24.42
Price / Sales	3.88	304.30	514.65	112.54
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	0.46	8.32	10.69	6.82
Net Income	-$218.96M	$23.94M	$3.57B	$337.56M
7 Day Performance	-1.46%	1.84%	0.61%	1.16%
1 Month Performance	-8.99%	-0.04%	1.56%	3.16%
1 Year Performance	-51.61%	44.82%	25.44%	30.60%

Bicycle Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCYC Bicycle Therapeutics	3.746 of 5 stars	$4.05 flat	$14.00 +245.7%	-51.6%	$282.73M	$72.86M	N/A	240	Positive News High Trading Volume
COAG Hemab Therapeutics	4.5776 of 5 stars	$27.13 -4.8%	$41.75 +53.9%	N/A	$1.27B	N/A	N/A	72	Quiet Period Expiration Gap Up
WVE WAVE Life Sciences	3.1204 of 5 stars	$6.26 -4.9%	$27.25 +335.3%	-15.5%	$1.27B	$71.80M	N/A	240
MPLT Maplight Therapeutics	3.5019 of 5 stars	$29.76 +1.5%	$37.78 +26.9%	N/A	$1.25B	N/A	N/A	109	Gap Up
PAHC Phibro Animal Health	4.8977 of 5 stars	$29.87 -3.0%	$38.80 +29.9%	+31.8%	$1.25B	$1.50B	12.82	2,475	Trending News Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCYC) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bicycle Therapeutics (BCYC) Competitors

BCYC vs. COAG, WVE, MPLT, PAHC, and MRVI

How does Bicycle Therapeutics compare to Hemab Therapeutics?

Summary

How does Bicycle Therapeutics compare to WAVE Life Sciences?

Summary

How does Bicycle Therapeutics compare to Maplight Therapeutics?

Summary

How does Bicycle Therapeutics compare to Phibro Animal Health?

Summary

How does Bicycle Therapeutics compare to Maravai LifeSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCYC vs. The Competition

Bicycle Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bicycle Therapeutics (BCYC) Competitors

BCYC vs. COAG, WVE, MPLT, PAHC, and MRVI

How does Bicycle Therapeutics compare to Hemab Therapeutics?

Does the media favor COAG or BCYC?

Do insiders and institutionals hold more shares of COAG or BCYC?

Do analysts rate COAG or BCYC?

Which has higher earnings & valuation, COAG or BCYC?

Is COAG or BCYC more profitable?

Summary

How does Bicycle Therapeutics compare to WAVE Life Sciences?

Is BCYC or WVE more profitable?

Do analysts rate BCYC or WVE?

Do institutionals & insiders have more ownership in BCYC or WVE?

Which has higher valuation & earnings, BCYC or WVE?

Does the media prefer BCYC or WVE?

Which has more volatility and risk, BCYC or WVE?

Summary

How does Bicycle Therapeutics compare to Maplight Therapeutics?

Do analysts prefer MPLT or BCYC?

Is MPLT or BCYC more profitable?

Does the media refer more to MPLT or BCYC?

Which has stronger earnings & valuation, MPLT or BCYC?

Do institutionals and insiders hold more shares of MPLT or BCYC?

Summary

How does Bicycle Therapeutics compare to Phibro Animal Health?

Do analysts prefer BCYC or PAHC?

Which has more risk & volatility, BCYC or PAHC?

Is BCYC or PAHC more profitable?

Does the media prefer BCYC or PAHC?

Do insiders & institutionals hold more shares of BCYC or PAHC?

Which has stronger valuation and earnings, BCYC or PAHC?

Summary

How does Bicycle Therapeutics compare to Maravai LifeSciences?

Is BCYC or MRVI more profitable?

Do analysts prefer BCYC or MRVI?

Does the media refer more to BCYC or MRVI?

Which has more volatility & risk, BCYC or MRVI?

Do institutionals and insiders believe in BCYC or MRVI?

Which has preferable valuation & earnings, BCYC or MRVI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCYC vs. The Competition

Bicycle Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools